Sunvozertinib

A targeted therapy for non-small cell lung cancer

Sunvozertinib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Sunvozertinib is an investigational tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC). It specifically targets mutations in the epidermal growth factor receptor (EGFR), which are commonly associated with resistance to first-line EGFR inhibitors.

Mechanism of Action

Sunvozertinib functions by selectively inhibiting the activity of mutant forms of the EGFR, particularly those with the T790M mutation, which is a common mechanism of resistance to earlier generations of EGFR inhibitors. By binding to the ATP-binding site of the mutant EGFR, Sunvozertinib prevents the activation of downstream signaling pathways that promote cell proliferation and survival.

Clinical Development

Sunvozertinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with advanced NSCLC who have developed resistance to other EGFR-targeted therapies. Preliminary results have shown promising activity in patients with EGFR mutations, including those with central nervous system metastases.

Pharmacokinetics

The pharmacokinetic profile of Sunvozertinib is characterized by its oral bioavailability and its ability to penetrate the blood-brain barrier, making it a potential treatment option for NSCLC patients with brain metastases. The drug is metabolized primarily in the liver and excreted through both renal and fecal pathways.

Adverse Effects

Common adverse effects associated with Sunvozertinib include diarrhea, rash, and nausea. More serious side effects may include interstitial lung disease and hepatotoxicity, which require careful monitoring during treatment.

Related Pages

• Non-small cell lung cancer
• Tyrosine kinase inhibitor
• Epidermal growth factor receptor
• Cancer treatment